COMMUNIQUÉS West-GlobeNewswire

The Hemp Doctor Expands With Third Store Location in Huntersville, NC
18/12/2024
MOORESVILLE, N.C., Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Hemp Doctor, an online and physical store retailer of hemp-derived products in the US, opens its third store location in Northlake Mall, 9548 Mt. Holly- [...]
HWH International Inc. Provides Updates on Travel Joint Venture
18/12/2024
BETHESDA, MD, Dec. 18, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH” or the “Company”) (Nasdaq: HWH) is pleased to provide an update on the progress of a joint venture in its Hapi Travel business, in which HWH [...]
Healthcare Integrated Technologies welcomes Katie Piperata as Consultant for its Healthcare Division
18/12/2024
Knoxville, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, proudly announces the engagement of Katie Piperata as a [...]
Longeveron to Present at Biotech Showcase 2025
18/12/2024
MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Braille Institute Library to Host Livestream Event with Pulitzer Prize Finalist Andrew Leland on January 16, 2025
18/12/2024
Leland to discuss his best-selling book, “The Country of the Blind: A Memoir at the End of Sight” LOS ANGELES, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Braille Institute Library is excited to announce a special event [...]
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
18/12/2024
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to [...]
Rafarma pharmaceutical updates
18/12/2024
Sheridan, Wyoming, USA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) Dear Rafarma shareholders, We apologize for the delay in providing information about the company's activities in recent [...]
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
18/12/2024
Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis tests LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of [...]
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
18/12/2024
Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’ acquisition of Catalent [...]
Akari Therapeutics Announces Key Leadership Appointments
18/12/2024
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced [...]
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
18/12/2024
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
18/12/2024
JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today [...]
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
18/12/2024
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today [...]
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
18/12/2024
Trial will evaluate the safety, pharmacokinetics and pharmacodynamics of RPT1G in adult healthy volunteers in anticipation of their upcoming oncology trial to treat patients with acute myeloid leukemia (AML) and high- [...]
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
18/12/2024
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, [...]
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
18/12/2024
Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of Testing Significant Improvement in Skin Appearance Observed in Pediatric Study after Only 12 Days of Dosing [...]
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
18/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the [...]
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
18/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna , a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., [...]
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
18/12/2024
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A [...]

Pages